Sampo plc: Managers’ Transactions (Wahlroos/Columba AS)
SAMPO PLC MANAGERS’ TRANSACTIONS 10 May 2022 at 11:20 am
Sampo plc: Managers’ Transactions(Wahlroos/Columba AS)
Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation.
The transaction concerns the change of ownership in Columba AS. After the transaction, Wahlroos doesn’t have controlling interest in Columba AS.
____________________________________________
Person subject to the notification requirement
Name: Björn Wahlroos
Position: Member of the Board/Deputy member
Issuer: Sampo plc
LEI: 743700UF3RL386WIDA22
Notification type: INITIAL NOTIFICATION
Reference number: 14596/5/6
____________________________________________
Transaction date: 2022-05-05
Venue not applicable
Instrument type: SHARE
ISIN: FI0009003305
Nature of the transaction: GIFT,DONATION OR INHERITANCE (MADE)
Transaction details
(1): Volume: 570,000 Unit price: 0 N/A
Aggregated transactions
(1): Volume: 570,000 Volume weighted average price: 0 N/A
SAMPO PLC
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
London Stock Exchange
Financial Supervisory Authority
The principal media
www.sampo.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 202423.4.2024 08:15:00 CEST | Press release
PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023 Ghent, Belgium – 23 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Annual and Extraordinary General Meetings of Shareholders on Thursday, 23 May 2024. The annual report for the financial year 2023 has been published on Sequana Medical's website and can be accessed here. The items on the agendas of the meetings include (among other) the proposed approval of a number of resolutions relating to the financial year ended 31 December 2023, the proposed approval of the revised remuneration policy, the proposed reappointment of the statutory auditor, the application of Article 7:151 of t
KBC Group: Update regarding the KBC Group share buyback programme23.4.2024 08:00:00 CEST | Press release
Within the framework of the share buyback programme announced on 10 August 2023 after trading hours, KBC Group NV wishes to advise that the following transactions took place on Euronext Brussels’ regulated market between 15 April 2024 and 19 April 2024, included: Date No. of shares Total price Average price Lowest price Highest price 15-04-2024 72 000 € 4 947 120 € 68.71 € 68.40 € 69.24 16-04-2024 75 000 € 5 071 792 € 67.62 € 67.28 € 68.00 17-04-2024 72 000 € 4 941 259 € 68.63 € 67.90 € 69.24 18-04-2024 70 000 € 4 883 179 € 69.76 € 69.08 € 70.00 19-04-2024 70 000 € 4 854 325 € 69.35 € 68.20 € 69.78 Following these transactions, the total number of own shares held by KBC Group NV within the framework of the share buyback programme amounted to 14 844 378 on 19 April 2024, for a total consideration of € 883 158 497. This information is also available at https://www.kbc.com/en/share-buy-back Attachment 20240423-pb-buyback-en
Garry Menzel joins GHO Capital as Operating Partner23.4.2024 08:00:00 CEST | Press release
Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR² Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering healthcare companies London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner. Garry brings a unique blend of scientific, strategic, investment and operating skills with diverse experiences from more than 25 years of building healthcare businesses and leading high-performing teams. Most recently he was President and Chief Executive Officer of immunotherapy company TCR² Therapeutics, leading it from concept to clinical trial success before its merger with Adaptimmune (Nasdaq: ADAP) in March 2023 where he became a member of the Board. Prior to TCR² Therapeutics, Garry was the Chief Financial Officer of Da
Innofactor Plc’s Interim Report for January 1–March 31, 2024 (IFRS)23.4.2024 08:00:00 CEST | Press release
Innofactor Plc Interim Report April 23, 2024, at 9:00 Finnish time Innofactor increased its net sales in the first quarter of 2024 in spite of the continued challenging market situation January–March 2024 in brief: Net sales were approximately EUR 21.2 million (2023: 20.2), representing an increase of 4.8%The operating margin was approximately EUR 2.6 million (2023: 2.5), which shows an increase of 4.6% Operating profit was EUR 1.8 million (2023: 1.7), representing an increase of 7.3%The order backlog at the end of the review period was EUR 68.8 million (2023: 76.3), representing a decrease of 9.8% Key figures of the group, IFRS . Jan 1–Mar 31, 2024Jan 1–Mar 31, 2023Change Net sales, EUR thousand 21,186 20,223 4.8% Growth of net sales 4.8% 19.2% Operating result before depreciation and amortization (EBITDA), EUR thousand 2,601 2,487 4.6% percentage of net sales 12.3% 12.3% Operating profit/loss (EBIT), EUR thousand 1,836 1,712 7.3% percentage of net sales 8.7% 8.5% Earnings before taxe
The new UNIQLO x Marimekko collaboration collection brings joyful patterns to a summer picnic23.4.2024 08:00:00 CEST | Press release
Marimekko Corporation, Press release, 23 April 2024 at 9.00 a.m. EEST Finnish lifestyle design house Marimekko and global apparel retailer UNIQLO will launch a new limited-edition collaboration collection in May 2024. The collection is made of simple and comfortable UNIQLO pieces and Marimekko’s timeless archive patterns that showcase the brand’s art of printmaking. The UNIQLO x Marimekko Summer 2024 limited-edition collection includes items for all ages from women to children and babies. The assortment offers a wide array of comfortable dresses, T-shirts and skirts. To perfect the looks, the line also features matching accessories, including the popular round mini shoulder bags in different Marimekko prints. “The overarching theme for this collection is the idea of a joyful summer picnic with friends and family. We are excited to bring some of our iconic archive prints to this colorful selection of UNIQLO’s easy summer dresses, matching accessories and more. Each item reflects the bol